Progress in Pediatric Cardiology
Volume 21, Issue 2 , Pages 211-217 , March 2006

Cell seeded tissue engineered cardiac valves based on allograft and xenograft scaffolds

References 

  1. Schmidt CE, Baier JM. Acellular vascular tissues: natural biomaterials for tissue repair and tissue engineering. Biomaterials. 2000;21(22):2215–2231
  2. Fuchs JR, Nasseri BA, Vacanti JP. Tissue engineering: a 21st century solution to surgical reconstruction. Ann Thorac Surg. 2001;72:577–591
  3. Bader A, Schilling T, Haverich A, et al. Tissue engineering of heart valves—human endothelial cell seeding of detergent acellularized porcine valves. Eur J Cardiothorac Surg. 1998;14:279–284
  4. Steinhoff G, Mertsching H, Haverich A, et al. Tissue engineering of pulmonary heart valves on allogenic acellular matrix conduits: in vivo restoration of valve tissue. Circulation. 2000;102:III50–III55
  5. Shinoka T, Breuer CK, Tanel RE, et al. Tissue engineering heart valves: valve leaflet replacement study in a lamb model. Ann Thorac Surg. 1995;60(6 Suppl):S513–S516
  6. O'Brien MF, Goldstein S, Walsh S, et al. The SynerGraft Valve: a new acellular (nonglutaraldehyde-fixed) tissue heart valve for autologous recellularization first experimental studies before clinical implantation. Semin Thorac Cardiovasc Surg. 1999;11(4 suppl I):194–200
  7. Cebotari S, Mertsching H, Kallenbach K, et al. Construction of autologous human heart valves based on an acellular allograft matrix. Circulation. 2002 (Sep 24);106(12 Suppl 1):I63–I68
  8. Hoerstrup SP, Kadner A, Breymann C, et al. Living, autologous pulmonary artery conduits tissue engineered from human umbilical cord cells. Ann Thorac Surg. 2002;74(1):46–52[discussion 52]
  9. Schoen FJ, Levy RJ. Founder's award, 25th annual meeting of the Society for Biomaterials, perspectives. Providence, RI, April 28–May 2, 1999. Tissue heart valves: current challenges and future research perspectives. J Biomed Mater Res. 1999;47(4):439–465
  10. Sauren AA, Kuijpers W, van Steenhoven AA, Veldpaus FE. Aortic valve histology and its relation with mechanics—preliminary report. J Biomech. 1980;13(2):97–104
  11. Schoen FJ. Aortic valve structure–function correlations: role of elastic fibers no longer a stretch of the imagination. J Heart Valve Dis. 1997;6(1):1–6
  12. Filip DA, Radu A, Simionescu M. Interstitial cells of the heart valves possess characteristics similar to smooth muscle cells. Circ Res. 1986;59(3):310–320
  13. Mulholland DL, Gotlieb AI. Cell biology of valvular interstitial cells. Can J Cardiol. 1996;12(3):231–236
  14. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg. 2005;79(3):1072–1080
  15. Mohler ER, Chawla MK, Chang AW, et al. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis. 1999;8(3):254–260
  16. Schenke-Layland K, Opitz F, Gross M, et al. Complete dynamic repopulation of decellularized heart valves by application of defined physical signals—an in vitro study. Cardiovasc Res. 2003;60(3):497–509
  17. Grauss RW, Hazekamp MG, van Vliet S, Gittenberger-de Groot AC, DeRuiter MC. Decellularization of rat aortic valve allografts reduces leaflet destruction and extracellular matrix remodeling. J Thorac Cardiovasc Surg. 2003;126(6):2003–2010
  18. Rieder E, Kasimir MT, Silberhumer G, et al. Decellularization protocols of porcine heart valves differ importantly in efficiency of cell removal and susceptibility of the matrix to recellularization with human vascular cells. J Thorac Cardiovasc Surg. 2004;127(2):399–405
  19. Nishi C, Nakajima N, Ikada Y. In vitro evaluation of cytotoxicity of diepoxy compounds used for biomaterial modification. J Biomed Mater Res. 1995;29(7):829–834
  20. Augustin C, Damour O. Pharmacotoxicological applications of an equivalent dermis: three measurements of cytotoxicity. Cell Biol Toxicol. 1995;11(3–4):167–171
  21. Schoen FJ, Levy RJ. Heart valve bioprostheses: antimineralization. Eur J Cardiothorac Surg. 1992;6(Suppl 1):S91–S93[discussion S94]
  22. Webb CL, Schoen FJ, Flowers WE, Alfrey AC, Horton C, Levy RJ. Inhibition of mineralization of glutaraldehyde-pretreated bovine pericardium by AlCl3. Am J Pathol. 1991;138(4):971–981
  23. O'Brien MF, Goldstein S, Walsh S, Black KS, Elkins R, Clarke D. The SynerGraft valve: a new acellular (nonglutaraldehyde-fixed) tissue heart valve for autologous recellularization first experimental studies before clinical implantation. Semin Thorac Cardiovasc Surg. 1999;11(4 Suppl 1):194–200
  24. Simon P, Kasimir MT, Seebacher G, et al. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg. 2003;23(6):1002–1006[discussion 1006]
  25. Rieder E, Seebacher G, Kasimir MT, et al. Tissue engineering of heart valves: decellularized porcine and human valve scaffolds differ importantly in residual potential to attract monocytic cells. Circulation. 2005;111(21):2792–2797
  26. Goncalves AC, Griffiths LG, Anthony RV, Orton EC. Decellularization of bovine pericardium for tissue-engineering by targeted removal of xenoantigens. J Heart Valve Dis. 2005;14(2):212–217
  27. Mertsching H, Karim N, Haverich A, Bader A. Investigations on biological safety and immunologic aspects of chimeric bioartificial vessels in xenotransplantation. Transplant Proc. 2000;32(5):1165
  28. Moza AK, Mertsching H, Herden T, Bader A, Haverich A. Heart valves from pigs and the porcine endogenous retrovirus: experimental and clinical data to assess the probability of porcine endogenous retrovirus infection in human subjects. J Thorac Cardiovasc Surg. 2001;121(4):697–701
  29. Grande KJ, Kunzelman KS, David TE, et al. Porcine aortic leaflet arrangement may contribute to clinical xenograft failure. ASAIO J. 1993;39:918–922
  30. Elkins RC, Dawson PE, Goldstein S, et al. Decellularized human valve allografts. Ann Thorac Surg. 2001;71:S428–S432
  31. Dohmen PM, Lembcke A, Hotz H, Kivelitz D, Konertz WF. Ross operation with a tissue-engineered heart valve. Ann Thorac Surg. 2002;74(5):1438–1442
  32. Bechtel JF, Gellissen J, Erasmi AW, et al. Mid-term findings on echocardiography and computed tomography after RVOT-reconstruction: comparison of decellularized (SynerGraft) and conventional allografts. Eur J Cardiothorac Surg. 2005;27(3):410–415[discussion 415]
  33. da Costa FD, Dohmen PM, Duarte D, et al. Immunological and echocardiographic evaluation of decellularized versus cryopreserved allografts during the Ross operation. Eur J Cardiothorac Surg. 2005;27(4):572–578
  34. Goldstein S, Clarke DR, O'Brien MF, et al. Transpecies heart valve transplant: advanced studies of a bioengineered xeno-autograft. Ann Thorac Surg. 2000;70:1962–1969
  35. Walluscheck KP, Steinhoff G, Haverich A. Endothelial cell seeding of native vascular surfaces. Eur J Vasc Endovasc Surg. 1996;11:290–303
  36. Allaire E, Guettier C, Michel JB. Cell-free arterial grafts: morphologic characteristics of aortic isografts, allografts, and xenografts in rats. J Vasc Surg. 1994;19:446–456
  37. Shinoka T, Ma PX, Shum-Tim D, et al. Tissue-engineered heart valves. Autologous valve leaflet replacement study in a lamb model. Circulation. 1996;94(9 Suppl):II164–II168
  38. Schnell AM, Hoerstrup SP, Zund G, et al. Optimal cell source for cardiovascular tissue engineering: venous vs. aortic human myofibroblasts. Thorac Cardiovasc Surg. 2001;49(4):221–225
  39. Perry TE, Kaushal S, Sutherland FW, et al. Bone marrow as a cell source for tissue engineering heart valves. Ann Thorac Surg. 2003;75(3):761–767[discussion 767]
  40. Hoerstrup SP, Kadner A, Melnitchouk S, et al. Tissue engineering of functional trileaflet heart valves from human marrow stromal cells. Circulation. 2002;106(12 Suppl 1):I143–I150
  41. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964–967
  42. Kaushal S, Amiel GE, Guleserian KJ, et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat Med. 2001;7(9):1035–1040
  43. Mertsching H, Walles T, Hofmann M, Schanz J, Knapp WH. Engineering of a vascularized scaffold for artificial tissue and organ generation. Biomaterials. 2005;26(33):6610–6617
  44. Schmidt D, Mol A, Neuenschwander S, et al. Living patches engineered from human umbilical cord derived fibroblasts and endothelial progenitor cells. Eur J Cardiothorac Surg. 2005;27(5):795–800
  45. Schmidt D, Breymann C, Weber A, et al. Umbilical cord blood derived endothelial progenitor cells for tissue engineering of vascular grafts. Ann Thorac Surg. 2004;78(6):2094–2098
  46. Engelmayr GC, Hildebrand DK, Sutherland FW, Mayer JE, Sacks MS. A novel bioreactor for the dynamic flexural stimulation of tissue engineered heart valve biomaterials. Biomaterials. 2003;24(14):2523–2532
  47. Barron V, Lyons E, Stenson-Cox C, McHugh PE, Pandit A. Bioreactors for cardiovascular cell and tissue growth: a review. Ann Biomed Eng. 2003;31(9):1017–1030
  48. Hildebrand DK, Wu ZJ, Mayer JE, Sacks MS. Design and hydrodynamic evaluation of a novel pulsatile bioreactor for biologically active heart valves. Ann Biomed Eng. 2004;32(8):1039–1049
  49. Lichtenberg A, Tudorache I, Cebotari S, Ringes-Lichtenberg S, Höffler K, Haverich A. Tissue engineering of heart valves based on biological matrix using controlled physiological dynamic environment. Circulation. 2004;(Supplement III):361

PII: S1058-9813(05)00087-1

doi: 10.1016/j.ppedcard.2005.11.008

Progress in Pediatric Cardiology
Volume 21, Issue 2 , Pages 211-217 , March 2006

Article Tools

* Image Usage & Resolution